Business Wire

Finvasia Group Appoints Tajinder Virk as Interim CEO of ZuluTrade

Share

Finvasia today announced that it has appointed Tajinder Virk as the interim Chief Executive Officer for ZuluTrade. He will replace the previous CEO from the company, effective immediately.

"Tajinder has been instrumental in building upon Finvaisa’s success and has an impressive track record in delivering growth for our group companies," said Sarvjeet Singh Virk, CMD & Co-founder Finvasia. "We have seen Tajinder (A.K.A. Natty) in action first hand and have the utmost confidence that his deep financial experience and leadership skills will drive results and accelerate ZuluTrade’s business in this interim role."

Tajinder Virk is the CEO of Finvasia Group of companies and is an exceptional leader with deep familiarity with all aspects of the business that allows him to develop and lead the execution of the group’s strategic vision, assess risks and guide the group’s growth. He has worked with some of the largest investment banks and hedge funds on Wall Street and has managed multibillion-dollar funds for major US banks, before co-founding Finvasia. At ZuluTrade, Tajinder will work closely with the team to deliver on the business expansion plan.

Commenting on the appointment, Tajinder said, “Finvasia is known for its innovative business approach and for its ability to create value for its clients. We see ZuluTrade as the largest Social Wealth Management platform that will bring more asset classes and industry participants together under a single platform.

“ZuluTrade is among the largest and the original social trading platforms that revolutionised copy trading in 2008. ZuluTrade 2.0 will maintain its legacy of being broker neutral, so it has no conflict of interest with its investors. We will be offering a variety of asset classes, encouraging more investors, leaders and brokers to join the platform whilst creating a conducive environment for them to grow their wealth,” he continued.

Finvasia’s board has simultaneously commenced a formal search for a permanent CEO for ZuluTrade who can deliver on the Group’s expectations for future ready products while maintaining its core values and cultures.

About ZULUTRADE (https://www.zulutrade.com)

ZuluTrade is the original social trading platform that revolutionised copy trading in 2008. It offers a massive database of Algo signals and strategies currently available across the market, catering to both advanced and novice investors alike.

It's a broker neutral platform that has catered to over 2.5 million clients in over 100 countries and supports over twenty-six languages.

About FINVASIA (https://finvasia.com)

Finvasia is a multi-disciplinary, multinational organisation that owns and operates over a dozen brands across financial services, technology, real estate and healthcare verticals.

Finvasia Group has managed funds for some of the notable hedge funds of Wall street, launched the first and only commission free ecosystem for financial products in India and is now aggressively expanding its presence in the European market. The Group has provided technology to some of the notable listed and unlisted financial services entities across the globe.

Furthermore, its healthcare division recently launched a medically proven diabetes reversal program in India and has engaged scientists from various specialised fields in an effort to build nano and micro medical devices that will cater to the future of medical engineering.

In the last 13 years, Finvasia has catered to a few million clients in over 180 countries directly or via its subsidiaries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sandy Samra
ssamra@finvasia.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye